Myriad Genetics (MYGN) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MYGN shares.
View MYGN analyst ratings or view top-rated stocks.

4 brokerages have issued 12-month target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $24.00 to $32.00. On average, they predict the company's stock price to reach $26.60 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

Myriad Genetics' stock was trading at $14.51 at the beginning of 2023. Since then, MYGN shares have increased by 53.6% and is now trading at $22.29.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MYGN earnings forecast.

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $181.20 million for the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative trailing twelve-month return on equity of 7.42% and a negative net margin of 21.05%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the company posted ($0.14) earnings per share.

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Vanguard S&P Small-Cap 600 Value ETF (VIOV) and SPDR S&P 600 Small CapValue ETF (SLYV).

Myriad Genetics issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $732.49 million.

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.32%), Wellington Management Group LLP (8.25%), State Street Corp (5.64%), Glenview Capital Management LLC (5.14%), Bank of America Corp DE (4.21%) and Dimensional Fund Advisors LP (3.34%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYGN stock can currently be purchased for approximately $22.29.

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.82 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

The company employs 2,600 workers across the globe.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.